| Date Filed | Type | Description |
| 04/29/2021 |
GN
| Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update |
| 03/18/2021 |
GN
| Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma |
| 03/01/2021 |
GN
| Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update |
| 01/11/2021 |
GN
| Idera Pharmaceuticals to Present at Upcoming Conferences |
| 12/15/2020 |
GN
| Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million |
| 11/17/2020 |
GN
| Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer |
| 10/29/2020 |
GN
| Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update |
| 09/28/2020 |
GN
| Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037 |
| 09/15/2020 |
GN
| Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020 |
| 08/04/2020 |
GN
| Idera Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update |
| 07/15/2020 |
GN
| Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million |
| 06/02/2020 |
GN
| Idera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial for the Treatment of Micro-Satellite Stable Colorectal Cancer |
| 05/01/2020 |
GN
| Idera Pharmaceuticals Announces Change of Location for 2020 Annual Meeting of Stockholders |
| 04/30/2020 |
GN
| Idera Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update |
| 04/23/2020 |
GN
| Idera Pharmaceuticals Announces Tilsotolimod Program Updates to be Presented at AACR Virtual Annual Meeting 2020 |
| 04/21/2020 |
GN
| Idera Pharmaceuticals Announces Final Clinical Safety and Efficacy Data from ILLUMINATE-204 Trial in Advanced Melanoma |
| 04/07/2020 |
GN
| Idera Pharmaceuticals Announces Private Placement of up to $20.7 Million |
| 03/12/2020 |
GN
| Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update |
| 03/05/2020 |
GN
| Idera Pharmaceuticals Completes Enrollment in ILLUMINATE-301, its Registrational Trial of Tilsotolimod in Combination with Ipilimumab in Patients with Anti-PD-1 Refractory Advanced Melanoma |
| 01/14/2020 |
GN
| Idera Pharmaceuticals Provides 2020 Update and Outlook |
| 10/21/2019 |
GN
| Idera Pharmaceuticals Announces New U.S. Patent For Tilsotolimod Through September 2037 |
| 09/30/2019 |
GN
| Idera Pharmaceuticals Announces Initiation of the ILLUMINATE-206 Trial Evaluating Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors |
| 09/04/2019 |
GN
| Idera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration with AbbVie |
| 08/30/2019 |
GN
| Idera Pharmaceuticals to Present at the Baird 2019 Global Healthcare Conference |
| 07/23/2019 |
GN
| Idera Pharmaceuticals Announces Appointments of Elizabeth A. Tarka, MD, FACC as Chief Medical Officer and John J. Kirby as Chief Financial Officer |
| 06/18/2019 |
GN
| Idera Pharmaceuticals to Present at the 2019 JMP Securities Life Sciences Conference |
| 05/02/2019 |
GN
| Idera Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update |
| 04/10/2019 |
GN
| Idera Pharmaceuticals Provides Corporate Update |
| 03/06/2019 |
GN
| Idera Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update |
| 02/27/2019 |
GN
| Idera Pharmaceuticals Completes Enrollment Into the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment |
| 12/18/2018 |
GN
| Idera Pharmaceuticals Announces Appointment of Carol A. Schafer to its Board of Directors |
| 12/14/2018 |
GN
| Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment |
| 12/12/2018 |
GN
| Idera Pharmaceuticals to Provide ILLUMINATE-204 Clinical Data Update on Friday, December 14, 2018 |
| 12/11/2018 |
GN
| United Parcel Service, Endurance International Group, Idera Pharmaceuticals, Aptevo Therapeutics, and Electro Scientific Industries — Future Expectations, Projections Moving into 2018 |